CSPC Again Ranked in Brand Finance China 500

Recently, Brand Finance, an international authoritative third-party brand value assessment and consulting agency, jointly with the Federation of Shenzhen Industries, released “Brand Finance China 500 2022 -The annual report on the most valuable and strongest Chinese brands” in Chinese and English. The list was unveiled at the 11th World Industrial Development Forum held in Shenzhen.

CSPC has been on the list for the second time.

As a prestigious brand value assessment and consulting agency, Brand Finance evaluates world-renowned brands across all industries, which is highly authoritative in the international arena.

11 pharmaceutical brands have been selected for the China 500 2022. CSPC has been on the list for two consecutive years since its first selection in 2021, maintaining the leading position among pharmaceutical brands.

Recently, the group was also listed as one of China’s 500 Most Valuable Brands by the World Brand Lab for the 17th consecutive year.

CSPC Exterior View

Thanks to the escalating R&D strength and market performance, CSPC sees a growing presence in the globe. As China deepens reform in the pharmaceutical industry, we have seized the opportunities of the industry’s transformation to achieve high-quality development through innovation. CSPC has grown into a domestic leading innovation-driven pharmaceutical company integrating R&D, production and sales.